Paychex Exposure Increased

  I last reviewed Paychex (PAYX) in this December 21, 2023 post at which time Q2 and YTD2024 results and an update to the FY2024 outlook had just been released. With the release of Q3 results and updated FY2024 outlook on April 2, I revisit this existing holding. Business Overview A Business Overview is provided [...]

By |April 3rd, 2024|Equity Investing|Comments Off on Paychex Exposure Increased

FFJ Portfolio – March 2024

This FFJ Portfolio - March 2024 report recaps my investment activity during the month of March. A snapshot of the holdings within the portfolio at the end of each month from December 2018 to March 2024 is accessible here. In December 2018, the FFJ Portfolio totals were: Core Accounts:  ~$350,809 CDN and ~$418,907 USD Side [...]

By |March 29th, 2024|FFJ Portfolio Holdings|Comments Off on FFJ Portfolio – March 2024

Automatic Data Processing (ADP) Is Overvalued

In my March 28 Automatic Data Processing (ADP) Is Overvalued guest post at Dividend Power, I lay out my rationale for not wanting to add to my current exposure. I have no idea how ADP's share price will behave in the very short term. I am, however, reasonably confident its share price will be higher [...]

By |March 28th, 2024|Equity Investing|Comments Off on Automatic Data Processing (ADP) Is Overvalued

Near Term Challenges Make Nike A BUY

I last reviewed Nike (NKE) in this December 22, 2023 post at which time I concluded that NKE's valuation did not warrant the purchase of additional shares. Now that NKE has released its Q3 and YTD2024 results and FY2024 outlook on March 21, I revisit this existing holding. In my opinion, the time to invest [...]

By |March 23rd, 2024|Equity Investing|Comments Off on Near Term Challenges Make Nike A BUY

FFJ Portfolio – February 2024

This FFJ Portfolio - February 2024 report recaps my investment activity during the month and in the first few days of March while I was on a ski trip. A snapshot of the holdings within the portfolio at the end of each month from December 2018 to February 29 is accessible here. In December 2018, [...]

By |March 21st, 2024|FFJ Portfolio Holdings|Comments Off on FFJ Portfolio – February 2024

Veeva Systems Added To The FFJ Portfolio

In my December 26, 2023 Veeva Systems (VEEV) post, I stated VEEV was on my 'Watch List'. In hindsight, I should have just acquired shares. Fast forward to February 29, and VEEV released its Q4 and FY2024 results and FY2025 guidance while I was on my ski trip to various resorts in British Columbia. Following [...]

By |March 21st, 2024|Equity Investing|Comments Off on Veeva Systems Added To The FFJ Portfolio

Mastercard Is Unreasonably Valued

I last reviewed Mastercard (MA) in my June 8, 2023 guest post at Dividend Power. At the time, the most recently available financial results were for Q1 2023. Now, based on my analysis of Q4 and FY2023 results and FY2024 outlook that were released on January 31, I conclude that Mastercard is unreasonably valued. In [...]

By |February 20th, 2024|Equity Investing|Comments Off on Mastercard Is Unreasonably Valued

West Pharmaceutical Expects A Challenging FY2024

I initiated a West Pharmaceutical (WST) position on November 25, 2022 with the purchase of 100 shares @ ~$225 in a 'Core' account within the FFJ Portfolio. I would have acquired more shares but we had just closed the purchase of an additional property which put a dent in my liquidity. By the time I [...]

By |February 17th, 2024|Equity Investing|Comments Off on West Pharmaceutical Expects A Challenging FY2024

Can CosMc’s Improve McDonald’s Results?

On February 15, my Can CosMc’s Improve McDonald’s Results? guest post was published at Dividend Power. McDonald's (MCD) has repeatedly boasted about its ability to raise menu prices without negatively impacting sales. A sizable segment of its customer base, however, is the lower income consumer. People can only put up with so much. Some are [...]

By |February 16th, 2024|Equity Investing|Comments Off on Can CosMc’s Improve McDonald’s Results?

Medpace Holdings Appears Richly Valued

I remain cautious in the current environment and am not looking to aggressively (1) initiate new positions and (2) increase my exposure to exiting holdings. Markets operate in cycles and inevitably, a major event or a series of events will trigger a broad market correction. While I do not invest in the broad market, the [...]

By |February 13th, 2024|Equity Investing|Comments Off on Medpace Holdings Appears Richly Valued
Go to Top